Key Highlights
- Q1 adjusted earnings per share reached $2.65, surpassing analyst expectations of $2.59
- Quarterly revenue totaled $15 billion, marking a 12% annual increase and exceeding the $14.72 billion consensus
- Immunology segment advanced 16%, while neuroscience soared 26% during the period
- Company elevated full-year 2026 adjusted EPS forecast to $14.08–$14.28 from previous $13.96–$14.16 range
- Shares climbed 2.5% in premarket session, clawing back portion of 13% year-to-date losses
When AbbVie entered Wednesday’s earnings announcement, the pharmaceutical giant was nursing a 13% year-to-date decline. But the company’s latest quarterly performance gave shareholders something to feel optimistic about.
The biopharmaceutical manufacturer disclosed first-quarter adjusted profit of $2.65 per share, climbing from $2.46 in the comparable period last year and topping the Street’s $2.59 projection. Top-line results reached $15 billion, representing a 12% year-over-year surge and exceeding analyst estimates of $14.72 billion.
ABBV shares advanced 2.5% to $202.63 during premarket hours on the news.
The revenue outperformance stemmed primarily from strength across two major business segments. The immunology division expanded 16%, while the neuroscience unit delivered an even more impressive 26% gain.
Skyrizi and Rinvoq remained the primary growth drivers within immunology. Skyrizi, prescribed for arthritis and Crohn’s disease treatment, delivered 31% revenue expansion during the quarter. Rinvoq contributed with 23% growth.
These advances successfully offset a 39% revenue drop from Humira. The former flagship medication faces mounting biosimilar competition, and its portfolio weight continues diminishing.
Upgraded Full-Year Forecast
AbbVie elevated its complete 2026 adjusted EPS projection to $14.08–$14.28, up from the previous $13.96–$14.16 target range. The Street’s current consensus stands at $14.12, positioning the refreshed midpoint modestly above expectations.
The forecast enhancement reflects management’s conviction in sustained performance from its immunology and neuroscience product portfolios.
On a generally accepted accounting principles basis, quarterly net profit totaled $695 million, translating to $0.39 per share. This compared to $1.29 billion, or $0.72 per share, during the year-ago quarter. The GAAP earnings decline year-over-year incorporates expenses excluded from adjusted calculations.
Looking at ABBV’s Trajectory
Shares had experienced selling pressure entering this release, down 13% for the year through Tuesday’s market close.
The 2.5% premarket gain indicates investors appreciated both the quarterly beat and upgraded guidance, although considerable recovery room remains.
Skyrizi and Rinvoq now unmistakably power AbbVie’s expansion narrative, with their combined results easily compensating for Humira’s persistent decline.
The neuroscience division is emerging as a more substantial growth contributor. The segment’s 26% expansion rate demonstrates meaningful progress beyond the flagship immunology business.
AbbVie’s $2.65 adjusted earnings represented the second straight quarter of annual growth on this measure, with the prior-year $2.46 figure now firmly surpassed.
The updated guidance band of $14.08–$14.28 in adjusted earnings establishes the full-year benchmark that market participants will track throughout the remainder of 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
